Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger
Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
IDG | is it close to death? | 25/05/21 | 5 | 2.3K | |||
|
|||||||
IDG | class action | 29/02/12 | 65 | 23K | |||
|
|||||||
IDG | capital reduction | 19/12/11 | 7 | 3.5K | |||
|
|||||||
IDG | Ann: Removal from the Official List | 26/08/11 | 0 | 767 | |||
|
|||||||
IDG | cancelled | 26/08/11 | 0 | 666 | |||
|
|||||||
IDG | Ann: ASIC FORM 484 - Cancellation of Shares | 26/08/11 | 0 | 926 | |||
|
|||||||
IDG | Ann: Suspension from Official Quotation | 19/08/11 | 0 | 827 | |||
|
|||||||
IDG | Ann: Final share buy-back notice - Appendix 3F | 18/08/11 | 0 | 811 | |||
|
See All Discussions